Keytruda (pembrolizumab)

pCPA File Number: 21138
Negotiation Status:
Concluded with an LOI
Indication(s):
Melanoma adjuvant therapy
Sponsor/Manufacturer:
Merck Canada Inc.
CDA-AMC Project Number:
PC0168-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: